BMO Equal Weight US Health Care Index ETF(ZHU-T) Rating
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 0
Stockchase rating for BMO Equal Weight US Health Care Index ETF is calculated according
to the stock experts' signals. A high score means experts
mostly recommend to buy the stock while a low score means
experts mostly recommend to sell the stock.
BMO Equal Weight US Health Care Index ETF(ZHU-T) Frequently Asked Questions
What is BMO Equal Weight US Health Care Index ETF stock symbol?
BMO Equal Weight US Health Care Index ETF is a Canadian stock, trading under the symbol
ZHU-T on the Toronto Stock Exchange
(ZHU-CT).
It is usually referred to as
TSX:ZHU or ZHU-T
Is BMO Equal Weight US Health Care Index ETF a buy or a sell?
In the last year, there was no coverage of BMO Equal Weight US Health Care Index ETF
published on Stockchase.
Is BMO Equal Weight US Health Care Index ETF a good investment or a top pick?
BMO Equal Weight US Health Care Index ETF was never recommended as a Top Pick
on Stockchase.
Read the latest stock experts ratings for BMO Equal Weight US Health Care Index ETF.
Why is BMO Equal Weight US Health Care Index ETF stock dropping?
Earnings reports or recent company news can cause the stock price to drop.
Read stock experts’ recommendations
for help on deciding if you should buy, sell or hold the stock.
Is BMO Equal Weight US Health Care Index ETF worth watching?
0 stock analysts
on Stockchase covered BMO Equal Weight US Health Care Index ETF In the last year.
It is a trending stock that is worth watching.
What is BMO Equal Weight US Health Care Index ETF stock price?
On 2024-12-04, BMO Equal Weight US Health Care Index ETF (ZHU-T)
stock closed at a price of $44.71.
A Canadian healthcare ETF Charges an MER of 0.35%. Healthcare in US election years is vulnerable as candidates target health costs. But industry fundamentals are improving. ZHU consists of 28% healthcare equipment and 22% biotech. To compare, XLV is 35% is pharma and only 13% in biotech.